FOLLOWING its approval by the TGA last year (PD 24 Nov 2025), cystic fibrosis (CF) drug Alyftrek (vanzacaftor/tezacaftor/deutivacaftor, Vertex) is now PBS-listed.
The drug is indicated for the treatment of people aged six years and older who meet the diagnostic criteria for CF and who have a responsive mutation in the CF transmembrane conductance regulator (CFTR) gene.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Feb 26
